Kewaunee Scientific Corporation reported third‑quarter fiscal 2026 results that showed a modest 3.3% rise in revenue to $69.4 million, driven by a 21.4% increase in international sales to $18.4 million and a 2.0% decline in domestic sales to $50.9 million. Pre‑tax earnings climbed 25.8% to $1.6 million, while diluted earnings per share fell to $0.23 from $0.45 a year earlier. Net earnings dropped to $692,000 from $1.354 million, and EBITDA increased to $3.8 million from $3.7 million year‑ago.
The domestic segment, which accounts for the majority of revenue, saw net earnings fall from $2.876 million to $2.290 million and EBITDA decline from $5.249 million to $4.096 million. International sales, however, grew strongly, contributing to the overall revenue gain. The company’s order backlog as of January 31, 2026 stood at $183.2 million, down from $221.6 million a year earlier but up from $214.6 million in April 2025, indicating a gradual erosion of future revenue streams.
Kewaunee’s growth strategy includes the recent acquisition of Nu Aire, which has begun to augment the company’s product portfolio and sales mix. Thomas D. Hull III, President and CEO, said, "Following the successful turnaround of the business, we embarked on a strategy that accelerated inorganic growth, which led to the successful completion of the Company's acquisition of Nu Aire." He added, "This dynamic validates our growth and diversification strategy and underscores the strength and resilience of our now broader laboratory products portfolio."
Margin compression is evident in the decline of net earnings despite revenue growth. The company’s pre‑tax earnings rose, reflecting improved operating leverage and cost control, but the larger drop in net earnings points to higher operating expenses or one‑time charges that eroded profitability. The EBITDA increase, while modest, suggests that the company is maintaining its operating margin in the face of rising costs, yet the net earnings decline signals that non‑operating items or higher interest and tax expenses are weighing on bottom‑line performance.
With no forward guidance disclosed, the company’s outlook hinges on its ability to sustain international growth and reinvigorate domestic demand while managing the integration of Nu Aire. The declining backlog and domestic sales headwinds underscore the need for renewed focus on core markets, whereas the robust international expansion offers a counterbalancing tailwind. Investors will likely monitor how the company addresses these challenges in the coming quarters.
The Q3 FY2026 results illustrate a company in transition: revenue growth is modest, profitability is under pressure, and strategic acquisitions are reshaping the business. The mixed performance signals that Kewaunee Scientific must navigate integration costs and domestic market softness while capitalizing on international momentum to maintain its competitive position.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.